Resources
BNET Resources
- sort by:
- Relevance
- Date
- Popularity
- How Pharma Stacks the Deck with Medical Journals
- How Pharma Stacks the Deck with Medical JournalsStatistical GymnasticsPublished on www.brainblogger.com:A Failed Attempt to Improve Misperceived Greatness: The ENHANCE TrialWhile it seems that pharmaceutical company sponsors of clinical trials usually end up with results that clearly favor their meds studied in their trial, there are rare exceptions, and Merck...
- Discussion threads 2008-06-18
- Schering-Plough Now in the Feds' Crosshairs
- The Vytorin scandal just got serious. Well, heck, it was already serious. Make this really serious: Investigation and Inquiries. Through the date of filing this 10-Q, Schering-Plough, the joint venture and/or its ...
- Blog posts 2008-05-07
- Is Merck Hanging Schering Out to Dry on Vytorin?
- A close reading of the Merck and Schering-Plough first-quarter conference calls suggests that Merck is distancing itself from its joint-venture partner -- who is, in any event, in a much worse position to weather the storm over their cholesterol-fighting pill Vytorin. Vytorin, of course, is a combination...
- Blog posts 2008-04-23
- Merck, Schering Unable to Stop Digging in Vytorin Mess
- As an example of how not to handle a corporate crisis, it's hard to beat the growing scandal over Vytorin. That's the blockbuster anti-cholesterol drug whose clinical-trial data Merck and Schering-Plough sat on for a year or two after it showed that Vytorin was apparently no better than a...
- Blog posts 2008-04-14
- Vytorin Update: Big Pharma Strikes Back
- The saga over Vytorin, the expensive cholesterol pill that may be no better than older, cheaper "statin" drugs, has come to a familiar pass: The manufacturer backlash. Merck and Schering-Plough, the makers of Vytorin, saw their stocks crushed the day after cardiologists trashed the multi-billion-dollar drug at...
- Blog posts 2008-04-03
- Vytorin Update: Big Pharma Strikes Back
- The saga over Vytorin, the expensive cholesterol pill that may be no better than older, cheaper "statin" drugs, has come to a familiar pass: The manufacturer backlash. Merck and Schering-Plough, the makers of Vytorin, saw their stocks crushed the day after cardiologists trashed the multi-billion-dollar drug at...
- Blog posts 2008-04-03
- Marketing Trumps Science in Vytorin Scandal
- In one of the drug industry's more revealing scandals in a while, Merck and Schering-Plough are struggling to rescue two new cholesterol drugs from evidence that they're useless at fighting heart disease and charges that the two companies deliberately sat on the bad news for roughly a year. ...
- Blog posts 2008-04-01
- Marketing Trumps Science in Vytorin Scandal
- In one of the drug industry's more revealing scandals in a while, Merck and Schering-Plough are struggling to rescue two new cholesterol drugs from evidence that they're useless at fighting heart disease and charges that the two companies deliberately sat on the bad news for roughly a year. ...
- Blog posts 2008-04-01
Additional Resources
- Research and Markets: Determine the Impact of the ENHANCE Study on Vytorin and Zetia Use
- DUBLIN, Ireland -- Research and Markets (http://www.researchandmarkets.com/research/4e90d7/vytorin_wave_two) has announced the addition of the "Vytorin: Wave Two - Impact of ENHANCE Trial" report to their offering. A Survey of One-Hundred Three US-based PCP's and Cardiologists Deliverable: Survey with key findings. Study Description: Topic:...
- Articles 2008-06-23
- Schiffrin Barroway Topaz & Kessler, LLP Announces Court Ruling Relating to Merck & Co. Inc.'s Employee Savings & Security Plan, the Merck & Co., Inc. Employee Stock Purchase & Savings Plan, and the Merck Puerto Rico Employee Savings & Security Plan
- RADNOR, Pa., June 19 /PRNewswire/ -- ADVERTISEMENT - The following statement was issued today by the law firm of Schiffrin Barroway Topaz & Kessler, LLP: Schiffrin Barroway Topaz & Kessler, LLP is Co-Lead Counsel for the ERISA plaintiffs in the In re Merck & Co. Inc. Securities,...
- Articles 2008-06-19
- Zacks Analyst Blog Highlights: Merck, Alexza Pharmaceuticals, Eastman Chemical, Stoneridge and Abbott Laboratories
- CHICAGO -- Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Merck (NYSE: MRK), Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA), Eastman Chemical (NYSE:...
- Articles 2008-06-16
- Hagens Berman Appointed Co-Lead Counsel in Case Against Schering-Plough and Merck
- Lawsuit claims manufacturers misled consumers about the use of Zetia and Vytorin. SEATTLE, June 10 /PRNewswire/ -- Last week the U.S. District Court in New Jersey appointed Hagens Berman, along with four other firms, co-counsel in a case against Schering-Plough and Merck which claims the...
- Articles 2008-06-10
- WALL STREET CHOICE: VYTORIN/ZETIA DAMAGE IS NOT AS BAD AS FEARED
- Jami Rubin Morgan Stanley Stock: Schering-Plough Price target $20.00 Share price (as of April 4,2008) $16.12 52-Week Range $33.81-13.83 Significant stock sell-off for both Schering-Plough (-25%) and Merck (-15%) after the American College of Cardiology ACC conference thus far looks drastically disproportionate to the...
- Articles 2008-05-01
- Lack of transparency to blame for bad rap?
- ON JAN. 14, Schering-Plough released preliminary results of its ENHANCE clinical trial, finding that Vytorin (Zocor/Zetia) did nothing more than generic Zocor alone to slow the progression of plaques-in the carotid arteries of a smallish number of patients with a familial form of hypercholesterolemia who had previously been on statins....
- Articles 2008-05-01
- DTC REPORT: Update
- The European Federation of Pharmaceutical Industries and Associations said it doesn't want "push" TV, radio and print mass media for Rx drug info. Instead, the trade group proposed "push" info to be allowed only for disease awareness and "pull" info on specific medicines be allowed online. A New England...
- Articles 2008-05-01
- Antidote
- Even if I had another topic planned, how could I not write this month about Zetia? Another example of panacea to panic, another billion dollar drug toileted based on preliminary studies. More than 4 million Americans taking this drug or the combination drug Vytorin Zetia plus Zocor now not sure...
- Articles 2008-05-01
- eFoodSafety's Cinnechol™ Positioned to Make In-Roads in Cholesterol Market
- Sixteen Million Americans Currently Take Cholesterol Medications SCOTTSDALE, Ariz. -- Cholesterol-lowering drugs comprise the largest drugs class in the U.S., amounting to over $20 billion annually. Of that total, revenue for the top three selling prescription drugs in this category - Vytorin, Zocor, and Lipitor - has historically...
- Articles 2008-04-24
- Schering-Plough CEO Buys $2 Million in Common Shares
- KENILWORTH, N.J., April 24 /PRNewswire-FirstCall/ -- Schering-Plough Corporation announced today that Chairman and CEO Fred Hassan purchased just over $2 million of Schering-Plough common stock, or 110, 000 shares at an average purchase price of $18.26 per share. "As I said when I announced my intention to...
- Articles 2008-04-24
- Vytorin Coverage with Leading Health Plans Revisited - See Uptake of Generic Simvastatin and Crestor Without Need for Widespread Formulary Changes
- PHILADELPHIA -- According to follow-up research from Cognet-X, Inc., conducted in the first week of April, pharmacy and medical executives at leading health plans still do not foresee widespread changes in how their organizations will cover Merck/Schering-Plough's cholesterol reducer Vytorin. Among the reasons: more than three-quarters of those...
- Articles 2008-04-21
- Physicians and Patients Nationwide Discuss Controversial Results of Recent Cholesterol Lowering Study
- Sermo Survey of Hundreds of Physicians Reveals Unexpected Outcomes CAMBRIDGE, Mass. -- Sermo (http://www.sermo.com), the largest physician-only online community, today announced the results of a physician survey prompted by the swirl of media coverage following the release of ENHANCE trial data at the recent American College of Cardiology...
- Articles 2008-04-09
- << Previous
- page 1 of 1
- Next >>
Content Types
Premier Vendor Content Whitepapers, webcasts & resources from our Power Center Sponsors
- Create new ways to live, work and play with Intel
-
Learn how Intel researchers around the world are developing with tera-scale computing, wireless computing anywhere on earth, advanced exploratory research, and more.
- Learn about new technology that improves every facet of life >>
- THE FUTURE JUST LOST ITS LEAD.
-
We're relentless about invention. Our latest technology includes hafnium-based circuitry, mobile technology for a new generation of MIDs, and 32 nanometer processing.
- Learn more >>
- Dell: Built to fit your business needs.
-
Powerful, Dell is built to fit your business needs Customized systems, experts trained in small business, 24/7/365 support, and powerful, reliable technology. Dell, big results for small business.
- Learn More >>
